NSCLC Coverage From Every Angle
Advertisement
Advertisement

In the Medical Literature

Adding First-Line Ipilimumab to Chemotherapy for Squamous NSCLC
Fat Intake and Risk of Lung Cancer
COPD Treatment Initiative for Patients With Lung Cancer
Frequency of Lung Cancer in Never-Smokers in the UK
Surfactant Protein D and Clinical Outcomes in Lung Cancer
Use of Supplemental Vitamin B and Risk of Lung Cancer
Comparing Chemotherapy Regimens With Gemcitabine and Cisplatin in Advanced NSCLC
Combination Therapy With Apatinib in Resistant NSCLC
Updated Molecular Analyses in NSCLC Patients Treated With Erlotinib
Driver Mutations and Therapy Selection for Lung Adenocarcinoma
Concurrent Chemotherapy and Proton Therapy in Advanced Lung Cancer
Robot-Assisted Thoracic Surgery for Lung Lobectomy in NSCLC
Brigatinib in Crizotinib-Refractory ALK-Positive Non–Small Cell Lung Cancer
Nivolumab in the First-Line Treatment of Advanced or Recurrent Lung Cancer
Atezolizumab in PD-L1–Selected Advanced Non–Small Cell Lung Cancer
Cost Analysis of Personalized vs Fixed Dosing of Pembrolizumab
Alectinib and CNS Response in Resistant ALK-Positive Disease
Alectinib vs Crizotinib in ALK-Positive NSCLC
Potential Biomarker in Lung Squamous Cell Carcinoma
Early-Phase Trial of Vaccine in NSCLC
Brigatinib in Patients With Crizotinib-Refractory ALK–Positive NSCLC
Local Ablative Therapy for Oligometastatic Lung Cancer
Addition of Selumetinib to Docetaxel in KRAS-Mutant Lung Cancer
Chromosome Instability: Potential Prognostic Predictor in Lung Cancer
Multikinase Inhibitors in RET-Rearranged NSCLC
A Population-Based Comparative Effectiveness Study of Chemoradiation Regimens and Sequences in Stage III NSCLC
Osimertinib or Platinum/Pemetrexed in EGFR T790M–Positive Lung Cancer
Impact of Reflex EGFR/ALK Testing on Time to Treatment of Patients With Advanced Nonsquamous NSCLC
Proportion of Never-Smoker NSCLC Patients at Three Diverse Institutions
Atezolizumab vs Docetaxel in Patients With Previously Treated NSCLC (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial
Management Strategies for Adverse Events Associated With EGFR TKIs in NSCLC
Treatment of Stage IIIA NSCLC